Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. by Grifoni, Alba et al.
UC San Diego
UC San Diego Previously Published Works
Title
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease 
and Unexposed Individuals.
Permalink
https://escholarship.org/uc/item/56q617w2
Authors
Grifoni, Alba
Weiskopf, Daniela
Ramirez, Sydney I
et al.
Publication Date
2020-05-20
DOI
10.1016/j.cell.2020.05.015
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
  
Since January 2020 Elsevier has created a COVID-19 resource centre with 
free information in English and Mandarin on the novel coronavirus COVID-
19. The COVID-19 resource centre is hosted on Elsevier Connect, the 
company's public news and information website. 
 
Elsevier hereby grants permission to make all its COVID-19-related 
research that is available on the COVID-19 resource centre - including this 
research content - immediately available in PubMed Central and other 
publicly funded repositories, such as the WHO COVID database with rights 
for unrestricted research re-use and analyses in any form or by any means 
with acknowledgement of the original source. These permissions are 
granted for free by Elsevier for as long as the COVID-19 resource centre 
remains active. 
 
ArticleTargets of T Cell Responses to SARS-CoV-2
Coronavirus in Humans with COVID-19 Disease and
Unexposed IndividualsGraphical AbstractHighlightsd Measuring immunity to SARS-CoV-2 is key for
understanding COVID-19 and vaccine development
d Epitope pools detect CD4+ and CD8+ T cells in 100% and
70% of convalescent COVID patients
d T cell responses are focused not only on spike but also onM,
N, and other ORFs
d T cell reactivity to SARS-CoV-2 epitopes is also detected in
non-exposed individualsGrifoni et al., 2020, Cell 181, 1–13
June 25, 2020 ª 2020 Elsevier Inc.
https://doi.org/10.1016/j.cell.2020.05.015Authors
Alba Grifoni, Daniela Weiskopf,
Sydney I. Ramirez, ..., Davey M. Smith,
Shane Crotty, Alessandro Sette
Correspondence
shane@lji.org (S.C.),
alex@lji.org (A.S.)
In Brief
An analysis of immune cell responses to
SARS-CoV-2 from recovered patients
identifies the regions of the virus that is
targeted and also reveals cross-reactivity
with other common circulating
coronavirusesll
Please cite this article in press as: Grifoni et al., Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease
and Unexposed Individuals, Cell (2020), https://doi.org/10.1016/j.cell.2020.05.015llArticle
Targets of T Cell Responses to SARS-CoV-2
Coronavirus in Humans with COVID-19
Disease and Unexposed Individuals
Alba Grifoni,1 Daniela Weiskopf,1 Sydney I. Ramirez,1,2 Jose Mateus,1 Jennifer M. Dan,1,2
Carolyn Rydyznski Moderbacher,1 Stephen A. Rawlings,2 Aaron Sutherland,1 Lakshmanane Premkumar,3
Ramesh S. Jadi,3 Daniel Marrama,1 Aravinda M. de Silva,3 April Frazier,1 Aaron F. Carlin,2 Jason A. Greenbaum,1
Bjoern Peters,1,2 Florian Krammer,4 Davey M. Smith,2 Shane Crotty,1,2,5,* and Alessandro Sette1,2,5,6,*
1Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
2Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA
92037, USA
3Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7290, USA
4Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
5These authors contributed equally
6Lead Contact
*Correspondence: shane@lji.org (S.C.), alex@lji.org (A.S.)
https://doi.org/10.1016/j.cell.2020.05.015SUMMARYUnderstanding adaptive immunity to SARS-CoV-2 is important for vaccine development, interpreting coro-
navirus disease 2019 (COVID-19) pathogenesis, and calibration of pandemic control measures. Using HLA
class I and II predicted peptide ‘‘megapools,’’ circulating SARS-CoV-2-specific CD8+ and CD4+ T cells
were identified in 70% and 100% of COVID-19 convalescent patients, respectively. CD4+ T cell responses
to spike, the main target of most vaccine efforts, were robust and correlated with the magnitude of the anti-
SARS-CoV-2 IgG and IgA titers. The M, spike, and N proteins each accounted for 11%–27% of the total CD4+
response, with additional responses commonly targeting nsp3, nsp4, ORF3a, and ORF8, among others. For
CD8+ T cells, spike and M were recognized, with at least eight SARS-CoV-2 ORFs targeted. Importantly, we
detected SARS-CoV-2-reactive CD4+ T cells in 40%–60% of unexposed individuals, suggesting cross-
reactive T cell recognition between circulating ‘‘common cold’’ coronaviruses and SARS-CoV-2.INTRODUCTION
COVID-19 is a worldwide emergency. The first cases occurred in
December 2019, and now more than 240,000 deaths and
3,000,000 cases of SARS-CoV-2 infection have been reported
worldwide as of May 1st (Dong et al., 2020; Wu and McGoogan,
2020). Vaccines against SARS-CoV-2 are just beginning devel-
opment (Amanat and Krammer, 2020; Thanh Le et al., 2020).
An understanding of human T cell responses to SARS-CoV2 is
lacking, due to the rapid emergence of the pandemic. There is
an urgent need for foundational information about T cell
responses to this virus.
The first steps for such an understanding are the ability to quan-
tify the virus-specific CD4+ and CD8+ T cells. Such knowledge is
of immediate relevance, as it will provide insights into immunity
and pathogenesis of SARS-CoV-2 infection, and the same knowl-
edge will assist vaccine design and evaluation of candidate vac-
cines. Estimations of immunity are also central to epidemiological
model calibration of future social distancing pandemic control
measures (Kissler et al., 2020). Such projections are dramaticallydifferent depending on whether SARS-CoV-2 infection creates
substantial immunity, and whether any cross-reactive immunity
exists between SARS-CoV-2 and circulating seasonal ‘‘common
cold’’ human coronaviruses. Definition and assessment of human
antigen-specific SARS-CoV2 T cell responses are best made
with direct ex vivo T cell assays using broad-based epitope pools
and assays capable of detecting T cells of any cytokine polariza-
tion. Herein, we have completed such an assessment with blood
samples from COVID-19 patients.
There is also great uncertainty about whether adaptive im-
mune responses to SARS-CoV-2 are protective or pathogenic,
or whether both scenarios can occur depending on timing,
composition, or magnitude of the adaptive immune response.
Hypotheses range the full gamut (Peeples, 2020), based on avail-
able clinical data from severe acute respiratory disease
syndrome (SARS) or Middle East respiratory syndrome (MERS)
(Alshukairi et al., 2018;Wong et al., 2004; Zhao et al., 2017) or an-
imal model data with SARS in mice (Zhao et al., 2009, 2010,
2016), SARS in non-human primates (NHPs) (Liu et al., 2019; Ta-
kano et al., 2008) or feline infectious peritonitis virus (FIPV) in catsCell 181, 1–13, June 25, 2020 ª 2020 Elsevier Inc. 1
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Article(Vennema et al., 1990). Protective immunity, immunopathogene-
sis, and vaccine development for COVID-19 are each briefly dis-
cussed below, related to introducing the importance of defining
T cell responses to SARS-CoV-2.
Based on data from SARS patients in 2003–2004 (caused by
SARS-CoV, the most closely related human betacoronavirus to
SARS-CoV-2), and based on the fact that most acute viral infec-
tions result in development of protective immunity (Sallusto et al.,
2010), a likely possibility has been that substantial CD4+ T cell,
CD8+ T cell, and neutralizing antibody responses develop to
SARS-CoV-2, and all contribute to clearance of the acute infec-
tion, and, as a corollary, some of the T and B cells are retained
long term (i.e., multiple years) as immunological memory and
protective immunity against SARS-CoV-2 infection (Guo et al.,
2020b; Li et al., 2008). However, a contrarian viewpoint is also
legitimate. While most acute infections result in the development
of protective immunity, available data for human coronaviruses
suggest the possibility that substantive adaptive immune re-
sponses can fail to occur (Choe et al., 2017; Okba et al., 2019;
Zhao et al., 2017) and robust protective immunity can fail to
develop (Callow et al., 1990). A failure to develop protective im-
munity could occur due to a T cell and/or antibody response of
insufficient magnitude or durability, with the neutralizing anti-
body response being dependent on the CD4+ T cell response
(Crotty, 2019; Zhao et al., 2016). Thus, there is urgent need to un-
derstand the magnitude and composition of the human CD4+
and CD8+ T cell responses to SARS-CoV-2. If natural infection
with SARS-CoV-2 elicits potent CD4+ and CD8+ T cell responses
commonly associated with protective antiviral immunity, COVID-
19 is a strong candidate for rapid vaccine development.
Immunopathogenesis in COVID-19 is a serious concern (Cao,
2020; Peeples, 2020). It is most likely that an early CD4+ and
CD8+ T cell response against SARS-CoV-2 is protective, but an
early response is difficult to generate because of efficient innate
immune evasion mechanisms of SARS-CoV-2 in humans
(Blanco-Melo et al., 2020). Immune evasion by SARS-CoV-2 is
likely exacerbated by reduced myeloid cell antigen-presenting
cell (APC) function or availability in the elderly (Zhao et al., 2011).
In such cases, it is conceivable that late T cell responses may
instead amplify pathogenic inflammatory outcomes in the pres-
ence of sustained high viral loads in the lungs, by multiple hypo-
thetical possible mechanisms (Guo et al., 2020a; Li et al., 2008;
Liu et al., 2019). Critical (ICU) and fatal COVID-19 (and SARS) out-
comes are associated with elevated levels of inflammatory cyto-
kines and chemokines, including interleukin-6 (IL-6) (Giamarel-
los-Bourboulis et al., 2020; Wong et al., 2004; Zhou et al., 2020)
Vaccine development against acute viral infections classi-
cally focuses on vaccine-elicited recapitulation of the type of
protective immune response elicited by natural infection.
Such foundational knowledge is currently missing for
COVID-19, including how the balance and the phenotypes of
responding cells vary as a function of disease course and
severity. Such knowledge can guide selection of vaccine
strategies most likely to elicit protective immunity against
SARS-CoV-2. Furthermore, knowledge of the T cell responses
to COVID-19 can guide selection of appropriate immunolog-
ical endpoints for COVID-19 candidate vaccine clinical trials,
which are already starting.2 Cell 181, 1–13, June 25, 2020Limited information is also available about which SARS-CoV-2
proteins are recognized by human T cell immune responses. In
some infections, T cell responses are strongly biased toward
certain viral proteins, and the targets can vary substantially be-
tween CD4+ and CD8+ T cells (Moutaftsi et al., 2010; Tian
et al., 2019). Knowledge of SARS-CoV-2 proteins and epitopes
recognized by human T cell responses is of immediate rele-
vance, as it will allow for monitoring of COVID-19 immune re-
sponses in laboratories worldwide. Epitope knowledge will also
assist candidate vaccine design and facilitate evaluation of vac-
cine candidate immunogenicity. Almost all of the current COVID-
19 vaccine candidates are focused on the spike protein.
A final key issue to consider in the study of SARS-CoV-2 im-
munity is whether some degree of cross-reactive coronavirus
immunity exists in a fraction of the human population, and
whether this might influence susceptibility to COVID-19 disease.
This issue is also relevant for vaccine development, as cross-
reactive immunity could influence responsiveness to candidate
vaccines (Andrews et al., 2015).
In sum, the ability tomeasure and understand the humanCD4+
and CD8+ T cell responses to SARS-CoV-2 infection is a major
knowledge gap currently impeding COVID-19 vaccine develop-
ment, interpretation of COVID-19 disease pathogenesis, and
calibration of future social distancing pandemic control
measures.
RESULTS
SARS-CoV-2 Peptides and Predicted Class I and Class II
Epitopes
We recently predicted SARS-CoV-2 T cell epitopes utilizing
the Immune Epitope Database and Analysis Resource (IEDB)
(Dhanda et al., 2019; Vita et al., 2019). Utilizing bioinformatic
approaches, we identified specific peptides in SARS-CoV-2
with increased probability of being T cell targets (Grifoni
et al., 2020). We previously developed the megapool (MP)
approach to allow simultaneous testing of large numbers of
epitopes. By this technique, numerous epitopes are solubi-
lized, pooled, and re-lyophilized to avoid cell toxicity problems
(Carrasco Pro et al., 2015). These MPs have been used in hu-
man T cell studies of a number of indications, including al-
lergies (Hinz et al., 2016), tuberculosis (Lindestam Arlehamn
et al., 2016), tetanus, pertussis (Bancroft et al., 2016; da Silva
Antunes et al., 2017), and dengue virus, for both CD4+ and
CD8+ T cell epitopes (Grifoni et al., 2017; Weiskopf et al.,
2015). Here, we generated MPs based on predicted SARS-
CoV-2 epitopes. Specifically, one MP corresponds to 221 pre-
dicted HLA class II CD4+ T cell epitopes (Grifoni et al., 2020)
covering all proteins in the viral genome, apart from the spike
(S) antigen (CD4_R MP). The prediction strategy utilized is
geared to capture 50% of the total response (Dhanda
et al., 2018; Paul et al., 2015) and was designed and validated
to predict dominant epitopes independently of ethnicity and
HLA polymorphism. This approach takes advantage of the
extensive cross-reactivity and repertoire overlap between
different HLA class II loci and allelic variants to predict pro-
miscuous epitopes, capable of binding many of the most
common HLA class II prototypic specificities (Greenbaum
Table 1. Participant Characteristics
Age (years)
Unexposed (n = 20) COVID-19 (n = 20)
20–66
(median = 31,
IQR = 21)
20–64
(median = 44,
IQR = 9)
Gender
Male (%) 35% (7/20) 45% (9/20)
Female (%) 65% (13/20) 55% (11/20)
Residency
California (%) 95% (19/20) 100% (20/20)
USA, Non-California
(%)
5% (1/20) 0% (0/20)
Sample Collection
Date
March 2015–
March 2018
March–April 2020
SARS-CoV-2 PCR
Positivity
N/A 100% (16/16 tested)
Antibody Test
Positivitya
N/A 90% (18/20)
Disease Severityb
Mild N/A 70% (14/20)
Moderate N/A 20% (4/20)
Severe N/A 10% (2/20)
Critical N/A 0% (0/20)
Symptoms
Cough N/A 79% (15/19)
Fatigue N/A 42% (8/19)
Fever N/A 37% (7/19)
Anosmia N/A 21% (4/19)
Dyspnea N/A 16% (3/19)
Diarrhea N/A 5% (1/19)
Days Post Symptom
Onset at Collection
N/A 20–36 (18/20)
(median = 26, IQR = 7)
Past Medical History
No known N/A 65% (13/20)
Hyperlipidemia N/A 15% (3/20)
Hypertension N/A 10% (2/20)
Asthma N/A 10% (2/20)
Known or suspected
sick contact/exposure
N/A 75% (15/20)
aCommercial skin prick lateral flow assay.
bWHO criteria.
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For the spike protein, to ensure that all T cell reactivity
against this important antigen can be detected, we generated
a separate MP covering the entire antigen with 253 15-mer
peptides overlapping by 10-residues (MP_S, Table S1). As
stated above, the MP used to probe the non-spike regions is
expected to capture 50% of the total response. The use of
overlapping peptides spanning entire open reading frames
(ORFs) instead allows for a more complete characterization
but also requires more cells. This factor should be kept inmind in terms of comparison of the magnitude of the CD4+
T cell responses to those pools.
In the case of CD8 epitopes, since the overlap between
different HLA class I allelic variants and loci is more limited to
specific groups of alleles, or supertypes (Sidney et al., 2008),
we targeted a set of the 12 most prominent HLA class I A and
B alleles, which together allow broad coverage (>85%) of the
general population. Two class I MPs were synthesized based
on epitope predictions for those 12 most common HLA A and
B alleles (Grifoni et al., 2020), which collectively encompass
628 predicted HLA class I CD8+ T cell epitopes from the entire
SARS-CoV-2 proteome (CD8 MP-A and MP-B).
Immunological Phenotypes of Recovered COVID-19
Patients
To test for the generation of SARS-CoV-2 CD4+ and CD8+ T cell
responses following infection, we initially recruited 20 adult pa-
tients who had recovered from COVID-19 disease (Table 1).
We also utilized peripheral blood mononuclear cell (PBMC) and
plasma samples from local healthy control donors collected in
2015–2018 (see STAR Methods). Blood samples were collected
at 20–35 days post-symptoms onset from non-hospitalized
COVID-19 patients who were no longer symptomatic. SARS-
CoV-2 infection was determined by swab test viral PCR during
the acute phase of the infection. Verification of SARS-CoV-2
exposure was attempted both by lateral flow serology and
SARS-CoV-2 spike protein receptor binding domain (RBD)
ELISA (Stadlbauer et al., 2020), using plasma from the convales-
cence stage blood draw. Most patients were confirmed positive
by lateral flow immunoglobulin (Ig) tests (Table 1). All patients
were confirmed COVID-19 cases by SARS-CoV-2 RBD ELISA
(Figures 1 and S1). All cases were IgG positive; anti-RBD IgM
and IgA was also detected in the large majority of cases (Figures
1 and S1).
We defined a 21-color flow cytometry panel of mononuclear
leukocyte lineage and phenotypic markers (Table S2) to broadly
assess the immunological cellular profile of recovered COVID-19
patients (Figures 1 and S2). The frequency of CD3+ cells was
slightly increased in recovered COVID-19 patients relative to
non-exposed controls, while no significant differences overall
were observed in the frequencies of CD4+ or CD8+ T cells
between the two groups. Frequencies of CD19+ cells were
somewhat decreased, while no differences were observed in
the frequencies of CD3–CD19– cells or CD14+CD16– monocytes
(Figures 1 and S2). No evidence of general lymphopenia was
observed in the convalescing patients, consistent with the litera-
ture. Next, we utilized the SARS-CoV-2 MPs to probe CD4+ and
CD8+ T cell responses.
Identification and Quantitation of SARS-CoV-2-Specific
CD4+ T Cell Responses
We utilized T cell receptor (TCR) dependent activation induced
marker (AIM) assays to identify and quantify SARS-CoV-2-spe-
cific CD4+ T cells in recovered COVID-19 patients. Initial defini-
tion and assessment of human antigen-specific SARS-CoV-2
T cell responses are best made with direct ex vivo T cell assays
using broad-based epitope pools, such as MPs, and
assays capable of detecting T cells of unknown cytokineCell 181, 1–13, June 25, 2020 3
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Figure 1. SARS-CoV-2 IgM, IgA, and IgG Re-
sponses of Recovered COVID-19 Patients
(A–C) Plasma ELISA titers to SARS-CoV-2 spike RBD. (A)
IgG. (B) IgM. (C) IgA. Neg, unexposed donors from 2015–
2018 (n = 20); COVID, convalescing COVID-19 patients (n =
20). All data are shown as ELISA titers based on a standard.
The dotted line indicates limit of detection. Geometric
mean titers with geometric SDs are indicated.
(D–I) Immunophenotyping of mononuclear leukocytes.
Frequency of (D) CD3+ total T cells, (E) CD4+ T cells
(CD4+CD3+), (F) CD8+ T cells (CD8+CD3+), (G) CD19+ B
cells (CD19+CD3–), (H) CD3–CD19– cells, and (I)
CD14+CD16– monocytes (CD3–CD19–CD56–) from the
PBMCs of unexposed donors (Neg, n = 13) or convalescing
COVID-19 patients (COVID, n = 14). Data were analyzed
using the Mann-Whitney test with mean and standard de-
viation shown.
*p < 0.05, ****p < 0.0001. See also Figures S1 and S2.
ll
Please cite this article in press as: Grifoni et al., Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease
and Unexposed Individuals, Cell (2020), https://doi.org/10.1016/j.cell.2020.05.015
Articlepolarization and functional attributes. AIM assays are cytokine-
independent assays to identify antigen-specific CD4+ T cells
(Havenar-Daughton et al., 2016; Reiss et al., 2017). AIM assays
have been successfully used to identify virus-specific, vaccine-
specific, or tuberculosis-specific CD4+ T cells in a range of
studies (Dan et al., 2016, 2019; Herati et al., 2017; Morou
et al., 2019).
We stimulated PBMCs from 10 COVID-19 cases and 11
healthy controls (SARS-CoV-2 unexposed, collected in 2015–
2018) with a spike MP (MP_S) and the class II MP covering the
remainder of the SARS-CoV-2 orfeome (‘‘non-spike,’’ MP
CD4_R). A CMV MP was used as a positive control, while
DMSO was used as the negative control (Figures 2 and S3).
SARS-CoV-2 spike-specific CD4+ T cell responses
(OX40+CD137+) were detected in 100% of COVID-19 cases
(p < 0.0001 versus unexposed donors spike MP, Figures 2A
and 2B. p = 0.002 versus DMSO control, Figure 2C). CD4+
T cell responses to the remainder of the SARS-CoV-2 orfeome
were also detected in 100% of COVID-19 cases (p < 0.0079
versus unexposed donors non-spike MP, Figures 2A and 2B.
p = 0.002, non-spike versus DMSO control, Figure 2C). The
magnitude of the SARS-CoV-2-specific CD4+ T cell responses
measured was similar to that of the CMV MP (Figure S3C). The
concordance between SARS-CoV-2-specific CD4+ T cell mea-4 Cell 181, 1–13, June 25, 2020surements in independent experiments was
high (p < 0.0002, Figure S3D). To assess func-
tionality and polarization of the SARS-CoV-2-
specific CD4+ T cell response, we measured cy-
tokines secreted in response to MP stimulation.
The SARS-CoV-2-specific CD4+ T cells were
functional, as the cells produced IL-2 in
response to non-spike and spike MPs (Fig-
ure 2D). Polarization of the cells appeared to be
a classic TH1 type, as substantial interferon
(IFN)-g was produced (Figure 2E), while little to
no IL-4, IL-5, IL-13, or IL-17a was expressed
(Figures S3G–S3J).
Thus, recovered COVID-19 patients consis-
tently generated a substantial CD4+ T cellresponse against SARS-CoV-2. Similar conclusions were
reached using stimulation index as the metric (Figures S3E
and S3F). In terms of total CD4+ T cell response per donor (Fig-
ure 2A), on average 50% of the detected response was
directed against the spike protein, and 50% was directed
against the MP representing the remainder of the SARS-CoV-
2 orfeome (Figure 2A). This is of significance, since the SARS-
CoV-2 spike protein is a key component of the vast majority
of candidate COVID-19 vaccines under development. Of
note, given the nature of the MP_R peptide predictions, the
actual CD4+ T cell response to be ascribed to non-spike
ORFs was likely to be higher, addressed in further experiments
below.
Identification and Quantitation of SARS-CoV-2-Specific
CD8+ T Cell Responses
To measure SARS-CoV-2-specific CD8+ T cells in the recov-
ered COVID-19 patients, we utilized two complementary meth-
odologies, AIM assays and intracellular cytokine staining (ICS).
The two SARS-CoV-2 class I MPs were used, CD8-A and CD8-
B, with CMV MP and DMSO serving as positive and negative
controls, respectively (Figures 3 and S4). CD8+ T cell responses
were detected by AIM (CD69+CD137+) in 70% of COVID-19
cases (p < 0.0011 versus unexposed donors ‘‘CD8 total,’’
A B
C D E
Figure 2. SARS-CoV-2-Specific CD4+ T Cell Responses of Recovered COVID-19 Patients
(A) SARS-CoV-2-specific CD4+ T cells measured as percentage of AIM+ (OX40+CD137+) CD4+ T cells after stimulation of PBMCs with peptide pools encom-
passing spike only (Spike) MP or the CD4_R MP representing all the proteome without spike (Non-spike). Data were background subtracted against DMSO
negative control and are shown with geometric mean and geometric standard deviation. Samples were from unexposed donors (Unexposed, n = 11) and
recovered COVID-19 patients (COVID-19, n = 10).
(B) Fluorescence-activated cell sorting (FACS) plot examples, gated on total CD4+ T cells.
(C) AIM+ CD4+ T cell reactivity in COVID-19 cases between the negative control (DMSO) and antigen-specific stimulations.
(D and E) Cytokine levels in the supernatant of PBMCs from COVID-19 donors after stimulation with peptide pools (Spike and Non-spike) or the negative control
(DMSO). (D) IL-2. (E) IFN-g.
Statistical comparisons across cohorts were performed with the Mann-Whitney test. Pairwise comparisons (C–E) were performed with the Wilcoxon test. **p <
0.01; ***p < 0.001. See also Figure S3 and Table S6.
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ArticleFigures 3A and 3B; p = 0.002, CD8-A or CD8-B versus DMSO
control, Figure S4B). MP CD8-A contains spike epitopes,
among epitopes to other proteins. The magnitude of the
SARS-CoV-2 reactive CD8+ T cell responses measured by
AIM was somewhat lower than the CMV MP (Figure S4C).
Similar conclusions were reached using stimulation index (Fig-
ures S3D and S3E).
Independently, ICS assays detected IFN-g+ SARS-CoV-2-
specific CD8+ T cells in the majority of COVID-19 cases (Figures
3C and 3D). The majority of IFN-g+ cells co-expressed granzyme
B (Figures 3D and 3E). A substantial fraction of the IFN-g+
cells expressed tumor necrosis factor (TNF) but not IL-10 (Fig-
ure 3D). Thus, the majority of recovered COVID-19 patients
generated a CD8+ T cell response against SARS-CoV-2.
Relationship between SARS-CoV-2-Specific CD4+ T Cell
Responses and IgG and IgA Titers
Most protective antibody responses are dependent on CD4+
T cell help. Therefore, we assessed whether stronger SARS-
CoV-2-specific CD4+ T cell responses were associated withhigher antibody titers in COVID-19 cases. Given that spike is
the primary target of SARS neutralizing antibodies, we exam-
ined spike-specific CD4+ T cells. Spike-specific CD4+ T cell
responses correlated well with the magnitude of the anti-spike
RBD IgG titers (R = 0.81; p < 0.0001; Figure 4A). Similar re-
sults were obtained using stimulation index (Figure S5A).
The non-spike SARS-CoV-2-specific CD4+ T cell response
did not correlate as well with anti-spike RBD IgG titers (Fig-
ures 4B and S5B), consistent with a common requirement
for intramolecular CD4+ T cell help (Sette et al., 2008). Anti-
spike IgA titers also correlated with spike-specific CD4+
T cells (p < 0.0002, Figure S5). Thus, COVID-19 patients
make anti-spike RBD antibody responses commensurate
with the magnitude of their spike-specific CD4+ T cell
response. We then assessed the relationship between the
CD4+ and CD8+ T cell responses to SARS-CoV-2. SARS-
CoV-2-specific CD4+ and CD8+ T cell responses were well
correlated (R = 0.62. p = 0.0025, Figures 4C and S5). Thus,
antibody, CD4+, and CD8+ T cell responses to SARS-CoV-2
were generally well correlated.Cell 181, 1–13, June 25, 2020 5
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Figure 3. SARS-CoV-2-Specific CD8+ T Cell Responses by Recovered COVID-19 Patients
(A) SARS-CoV-2-specific CD8+ T cells measured as percentage of AIM+ (CD69+CD137+) CD8+ T cells after stimulation of PBMCs with class I MPs (CD8-A, CD8-
B, and the combined data [Total]). Data were background subtracted against DMSO negative control and are shown with geometric mean and geometric
standard deviation. Samples were from unexposed donors (Unexposed, n = 11) and recovered COVID-19 patients (COVID-19, n = 10).
(B) FACS plot examples.
(C) Percentage of CD8+ T cells producing IFN-g in response to SARS-CoV-2 MPs, or CMV MP, in PBMCs from COVID-19 and unexposed donors after back-
ground subtraction. Data are shown with geometric mean and geometric standard deviation.
(D) Functional profile of IFN-g+CD8+ T cells producing granzyme B (GzB), TNF-a (TNF), or IL-10 in response to SARS-CoV-2 MPs. Mean and SD are shown.
(E) FACS plot examples of IFN-g and granzyme B co-expression.
Statistical comparisons across cohorts were performed with the Mann-Whitney test. *p < 0.05; **p < 0.01.; ns not significant. See also Figure S4 and Table S6.
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T Cells
While spike- and non-spike-specific CD4+ T cell responses were
detectable in all COVID-19 cases, cells were also detected in un-
exposed individuals (Figures 3A and 3B). These responses were
statistically significant for non-spike-specific CD4+ T cell reac-
tivity (non-spike, p = 0.039; spike, p = 0.067; Figures 5A and
5B). Non-spike-specific CD4+ T cell responses were above the
limit of detection in 50% of donors based on stimulation index
(SI) (Figure S3E). All of the donors were recruited between
2015 and 2018, excluding any possibility of exposure to SARS-
CoV-2. Four human coronaviruses are known causes of sea-
sonal ‘‘common cold’’ upper-respiratory tract infections:
HCoV-OC43, HCoV-HKU1, HCoV-NL63, and HCoV-229E. We6 Cell 181, 1–13, June 25, 2020tested the SARS-CoV-2 unexposed donors for seroreactivity to
HCoV-OC43 and HCoV-NL63 as a representative betacoronavi-
rus and alphacoronavirus, respectively. All donors were IgG
seropositive to HCoV-OC43 and HCoV-NL63 RBD, to varying
degrees (Figure 5C), consistent with the endemic nature of these
viruses (Gorse et al., 2010; Huang et al., 2020; Severance et al.,
2008). We therefore examined whether these represented true
pan-coronavirus T cells capable of recognizing SARS-CoV-2
epitopes.
SARS-CoV-2 ORF Targets of CD4+ and CD8+ T Cells
A most pressing, yet unresolved, set of issues in understanding
SARS-CoV-2 immune responses is what antigens are targeted
by CD4+ and CD8+ T cells, whether the corresponding antigens
A B C
Figure 4. Correlations between SARS-CoV-2-Specific CD4+ T Cells, Antibodies, and CD8+ T Cells
(A) Correlation between SARS-CoV-2 spike-specific CD4+ T cells (%) and anti-spike RBD IgG.
(B) Correlation between SARS-CoV-2 non-spike-specific CD4+ T cells (%) and anti-spike RBD IgG.
(C) Correlation between SARS-CoV-2-specific CD4+ T cells and SARS-CoV-2-specific CD8+ T cells. Total MP responses per donor were used in each case
(‘‘Non-spike’’ + ‘‘spike’’ (CD4_R + MP_S) for CD4+ T cells, CD8_A + CD8_B for CD8+ T cells).
Statistical comparisons were performed using Spearman correlation. See also Figure S5.
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currently considered for COVID-19 vaccine development. We
synthesized sets of overlapping peptides spanning the entire
sequence of SARS-CoV-2 and pooled them separately so that
each pool would represent one antigen (with the exception of
nsp3, for which two pools were made; Table S1).
In the case of CD4+ T cell responses, no obvious pattern of
antigen specificity was observed based on SARS-CoV-2
genome organization; however, coronaviruses increase protein
synthesis of certain ORFs in infected cells via subgenomic
RNAs. Accounting for the relative abundance of subgenomic
RNAs (Figure 6A) (Irigoyen et al., 2016; Snijder et al., 2003;
Xie et al., 2020), the ORFs were re-ordered based on predicted
protein abundance (Figure 6B). A clear hierarchy of SARS-CoV-
2-specific CD4+ T cell targets was then apparent, with the ma-
jority of the CD4+ T cell response in COVID-19 cases directed
against highly expressed SARS-CoV-2 ORFs spike, M, and N.
On average, these antigens accounted for 27%, 21%, and
11% of the total CD4+ T cell response, respectively. Most
COVID-19 cases also had CD4+ T cells specific for SARS-
CoV-2 nsp3, nsp4, and ORF8 (Figure 6B), on average each ac-
counting for 5% of the total CD4+ T cell response (Figure 6C).
E, ORF6, hypothetical ORF10, and nsp1 are all small antigens
(or potentially not expressed, in the case of ORF10) and were
most likely predominantly unrecognized as a result. These re-
sults are somewhat unexpected, because data for other coro-
naviruses, from 27 different studies curated in the IEDB, re-
ported that spike accounted for nearly two-thirds of reported
CD4+ T cell reactivity (Table S3). N accounted for most of the
remaining epitopes in the published literature, although human
N-specific CD4+ T cell responses were not observed in one of
the most comprehensive studies of human SARS-CoV-1
T cell responses (Li et al., 2008). Coronavirus M has not previ-
ously been described as a prominent target of CD4+ T cell re-
sponses (Table S3). In sum, these results, fully scanning the
SARS2 orfeome, demonstrate a pattern of robust and diverse
SARS-CoV-2-specific CD4+ T cell reactivity in convalescing
COVID-19 cases that correlated largely with predicted viral pro-
tein abundance in infected cells.When examining the non-exposed donors, the pattern of CD4+
T cell targets changed. While S was still a relatively prominent
target (23%of total, on average), therewas no, ormarginal, reac-
tivity against SARS-CoV-2 N and M. Among donors with detect-
able CD4+ T cells, a shift in reactivity was observed toward
SARS-CoV-2 nsp14 (25%), nsp4 (15%) and nsp6 (14%) (Figures
6B and 6C). SARS-CoV-2-reactive CD4+ T cells were detected in
at least six different unexposed donors, demonstrating that the
cross-reactivity is relatively widely distributed (Figure S6A).
Having scanned the full SARS-CoV-2 orfeome for CD4+ T cell
reactivity in multiple donors, it was possible to assess whether
the epitope prediction MP approach successfully enriched for
SARS-CoV-2 epitopes targeted by human CD4+ T cells. When
the total reactivity observed with the CD4_R MP was plotted
versus the sum total of all antigen pools (excluding spike, given
that spike predictions were not included in the CD4_RMP), a sig-
nificant correlation was observed (p < 0.0002, Figure S6C). The
single MP-R captured 50% (44% +/ range 28%–80%) of
the non-spike response per COVID-19 donor, demonstrating
the success of the prediction approach, which, as mentioned
above, was devised to attempt to capture approximately 50%
of the total response (Dhanda et al., 2018; Paul et al., 2015).
In the case of CD8+ T cell responses, the data in the literature
from other coronaviruses (57 different studies curated in the
IEDB; Table S3) reported spike accounting for 50% and N ac-
counting for 36% of the defined epitopes. In a large study of hu-
man SARS-CoV-1 responses, spike was reported as essentially
the only target of CD8+ T cell responses (Li et al., 2008), while in a
study of MERS CD8+ T cells, responses were noted for spike, N
and a pool of M/E peptides (Zhao et al., 2017). Few epitopes
have been reported from other coronavirus antigens (Table
S3). Here, we scanned the full SARS-CoV-2 orfeome for CD8+
T cell recognition. Our data indicate a somewhat different pattern
of immunodominance for SARS-CoV-2 CD8+ T cell reactivity
(Figures 6D and 6E), with spike protein accounting for 26%
of the reactivity, and N accounting for 12%. Significant reac-
tivity in COVID-19 recovered subjects was derived from other
antigens, such as M (22%), nsp6 (15%), ORF8 (10%), and
ORF3a (7%) (Figures 6D and 6E). In unexposed donors, SARS-Cell 181, 1–13, June 25, 2020 7
A B C
Figure 5. SARS-CoV-2 Epitope Reactivity in Unexposed Individuals
(A) SARS-CoV-2-reactive CD4+ T cells measured as percentage of AIM+ (OX40+CD137+) CD4+ T cells in unexposed (n = 11) donors.
(B) FACS plot examples, gated on total CD4+ T cells.
(C) Plasma IgG ELISAs for seroreactivity to RBD of HCoV-OC43 or HCoV-NL63. Data are expressed as geometric mean and geometric SD.
Pairwise statistical comparisons (A) were performed with the Wilcoxon test. *p < 0.05; ns, not significant.
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different donors (Figure S7), with less clear targeting of specific
SARS-CoV-2 proteins than was observed for CD4+ T cells, sug-
gesting that coronavirus CD8+ T cell cross-reactivity exists but is
less widespread than CD4+ T cell cross-reactivity.
DISCUSSION
There is a critical need for foundational knowledge about T cell
responses to SARS-CoV-2. Here, we report functional validation
of predicted epitopes when arranged in epitope MPs, utilizing
PBMCs derived from convalescing COVID-19 cases. The exper-
iments also used protein-specific peptide pools to determine
which SARS-CoV-2 proteins are the predominant targets of hu-
man SARS-CoV-2-specific CD4+ and CD8+ T cells generated
during COVID-19 disease. Importantly, we utilized the exact
same series of experimental techniques with blood samples
from healthy control donors (PBMCs collected in the 2015–
2018 time frame), and substantial cross-reactive coronavirus
T cell memory was observed.
Our results demonstrate that the epitope MPs are reagents
well suited to analyze and detect SARS-CoV-2-specific T cell
responses with limited sample material. We also developed
and tested peptide pools corresponding to each of the 25 pro-
teins encoded in the SARS-CoV-2 genome. Data from both
the epitope MPs and protein peptide pool experiments can
be interpreted in the context of previously reported T cell
response immunodominance patterns observed for other co-
ronaviruses, particularly the SARS and MERS viruses, which
have been studied in humans, HLA-transgenic mice, wild-
type mice, and other species. In the case of CD4+ T cell re-
sponses, data for other coronaviruses found that spike ac-
counted for nearly two-thirds of reported CD4+ T cell reac-
tivity, with N and M accounting for limited reactivity, and no
reactivity in one large study of human SARS-CoV-1 responses
(Li et al., 2008). Our SARS-CoV-2 data reveal that the pattern
of immunodominance in COVID-19 is different. In particular,
M, spike, and N proteins were clearly co-dominant, each8 Cell 181, 1–13, June 25, 2020recognized by 100% of COVID-19 cases studied here. Signif-
icant CD4+ T cell responses were also directed against nsp3,
nsp4, ORF3s, ORF7a, nsp12, and ORF8. These data suggest
that a candidate COVID-19 vaccine consisting only of SARS-
CoV-2 spike would be capable of eliciting SARS-CoV-2-spe-
cific CD4+ T cell responses of similar representation to that
of natural COVID-19 disease, but the data also indicate that
there are many potential CD4+ T cell targets in SARS-CoV-2,
and inclusion of additional SARS-CoV-2 structural antigens
such as M and N would better mimic the natural SARS-CoV-
2-specific CD4+ T cell response observed in mild to moderate
COVID-19 disease.
Regarding SARS-CoV-2 CD8+ T cell responses, the pattern of
immunodominance found here differed from the literature for
other coronaviruses. However, stringent comparisons are not
possible, as some earlier studies were not similarly comprehen-
sive and did not utilize the same experimental strategy. The spike
protein was a target of human SARS-CoV-2 CD8+ T cell re-
sponses, but it is not dominant. SARS-CoV-2 M was just as
strongly recognized, and significant reactivity was noted for
other antigens, mostly nsp6, ORF3a, and N, which comprised
nearly 50% of the total CD8+ T cell response, on average.
Thus, these data indicate that candidate COVID-19 vaccines
endeavoring to elicit CD8+ T cell responses against the spike
protein will be eliciting a relatively narrow CD8+ T cell response
compared to the natural CD8+ T cell response observed in mild
to moderate COVID-19 disease. An optimal vaccine CD8+
T cell response to SARS-CoV-2 might benefit from additional
class I epitopes, such as the ones derived from the M, nsp6,
ORF3a, and/or N.
There have been concerns regarding vaccine enhancement of
disease by certain candidate COVID-19 vaccine approaches, via
antibody-dependent enhancement (ADE) or development of a
TH2 responses (Peeples, 2020). Herein, we saw predominant
TH1 responses in convalescing COVID-19 cases, with little to
no TH2 cytokines. Clearly more studies are required, but the
data here appear to predominantly represent a classic TH1
response to SARS-CoV-2.
AB C
D E
Figure 6. Protein Immunodominance of SARS-CoV-2-Specific CD4+ and CD8+ T Cells in COVID-19 Cases and Unexposed Donors
(A) SARS-CoV-2 genome organization and predicted viral protein abundance in infected cells.
(B) SARS-CoV-2 antigen-specific CD4+ T cells (AIM+, OX40+CD137+) quantified by stimulation index, using a peptide pool for each viral protein (with two ex-
ceptions, see Table S1). COVID-19 cases (top, in blue. n = 10) and unexposed donors (bottom, in white. n = 10). Data are expressed as geometric mean and
geometric SD.
(C) Fraction of SARS-CoV-2 proteins recognized by CD4+ T cells in COVID-19 cases (top) and unexposed donors (bottom).
(D) SARS-CoV-2 antigen-specific CD4+ T cells (AIM+, OX40+CD137+) quantified by stimulation index, using a peptide pool for each viral protein (with two ex-
ceptions, see Table S1). COVID-19 cases (top, in red. n = 10) and unexposed donors (bottom, in gray. n = 10). Data are expressed as geometric mean and
geometric SD.
(E) Fraction of SARS-CoV-2 proteins recognized by CD8+ T cells in COVID-19 cases (top) and unexposed donors (bottom).
See also Figures S6 and S7 and Table S6.
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sponses in COVID-19 cases, it is also of great interest to under-
stand whether cross-reactive immunity exists between corona-
viruses to any degree. A key step in developing that
understanding is to examine antigen-specific CD4+ and CD8+
T cells in COVID-19 cases and in unexposed healthy controls,
utilizing the exact same antigens and series of experimental
techniques. CD4+ T cell responses were detected in 40%–60%
of unexposed individuals. This may be reflective of some degree
of cross-reactive, preexisting immunity to SARS-CoV-2 in some,
but not all, individuals. Whether this immunity is relevant in influ-
encing clinical outcomes is unknown—and cannot be known
without T cell measurements before and after SARS-CoV-2
infection of individuals—but it is tempting to speculate that the
cross-reactive CD4+ T cells may be of value in protective immu-
nity, based on SARS mouse models (Zhao et al., 2016). Clear
identification of the cross-reactive peptides, and their sequence
homology relation to other coronaviruses, requires deconvolu-
tion of the positive peptide pools, which is not feasible with the
cell numbers presently available, and time frame of the pre-
sent study.
Regarding the value of cross-reactive T cells, influenza (flu)
immunology in relationship to pandemics may be instructive. In
the context of the 2009 H1N1 influenza pandemic, preexisting
T cell immunity existed in the adult population, which focused
on the more conserved internal influenza viral proteins (Green-
baum et al., 2009). The presence of cross-reactive T cells was
found to correlate with less severe disease (Sridhar et al.,
2013; Wilkinson et al., 2012). The frequent availability of cross-
reactive memory T cell responses might have been one factor
contributing to the lesser severity of the H1N1 flu pandemic
(Hancock et al., 2009). Cross-reactive immunity to influenza
strains has been modeled to be a critical influencer of suscepti-
bility to newly emerging, potentially pandemic, influenza strains
(Gostic et al., 2016). Given the severity of the ongoing COVID-
19 pandemic, it has been modeled that any degree of cross-pro-
tective coronavirus immunity in the population could have a very
substantial impact on the overall course of the pandemic, and
the dynamics of the epidemiology for years to come (Kissler
et al., 2020).
Limitations and Future Directions
Caveats of this study include the sample size and the focus on
non-hospitalized COVID-19 cases. Sample size was limited by
expediency. The focus on non-hospitalized cases of COVID-19
is a strength, in that these donors had uncomplicated disease
of moderate duration, and thus it was encouraging that substan-
tial CD4+ T cell and antibody responses were detected in all
cases, and CD8+ T cell responses in the majority of cases. Com-
plementing these data with MP T cell data from acute patients
and patients with complicated disease course will also be of
clear value, as will studies on the longevity of SARS-CoV-2
immunological memory. Additionally, lack of detailed informa-
tion on common cold history or matched blood samples pre-
exposure to SARS-CoV-2 prevents conclusions regarding the
abundance of cross-reactive coronavirus T cells before expo-
sure to SARS-CoV-2 and any potential protective efficacy of
such cells. Finally, full epitope mapping in the future will add10 Cell 181, 1–13, June 25, 2020important detailed resolution of the human coronavirus-specific
T cell responses.
In sum, we measured SARS-CoV-2-specific CD4+ and CD8+
T cells responses in COVID-19 cases. Using multiple
experimental approaches, SARS-CoV-2-specific CD4+ T cell
and antibody responses were observed in all COVID-19 cases,
and CD8+ T cell responses were observed in most. Importantly,
pre-existing SARS-CoV-2-cross-reactive T cell responses were
observed in healthy donors, indicating some potential for pre-ex-
isting immunity in the human population. ORF mapping of T cell
specificities revealed valuable targets for incorporation in candi-
date vaccine development and revealed distinct specificity pat-
terns between COVID-19 cases and unexposed healthy
controls.STAR+METHODS
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IEDB-AR (analysis resource) Dhanda et al., 2019 http://tools.iedb.org
NetMHCpan EL 4.0 Jurtz et al., 2017 http://tools.iedb.org/mhci/
IEDB Vita et al., 2019 https://www.iedb.org
Tepitool Paul et al., 2016; Paul et al., 2015 http://tools.iedb.org/tepitool/
FlowJo 10 FlowJo https://www.flowjo.com/
GraphPad Prism 8.4 GraphPad https://www.graphpad.com/
LEGENDplex v8.0 Biolegend https://www.biolegend.com/
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ArticleRESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Ales-
sandro Sette (alex@lji.org).
Materials Availability
Aliquots of synthesized sets of peptides utilized in this study will be made available upon request. There are restrictions to the avail-
ability of the peptide reagents due to cost and limited quantity.
Data and Code Availability
The published article includes all data generated or analyzed during this study, and summarized in the accompanying tables, figures
and Supplemental materials.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects
Healthy Unexposed Donors
Samples from healthy adult donors were obtained by the La Jolla Institute for Immunology (LJI) Clinical Core or provided by a
commercial vendor (Carter Blood Care) for prior, unrelated studies between early 2015 and early 2018. These samples were
considered to be from unexposed controls, given that SARS-CoV-2 emerged as a novel pathogen in late 2019, more than one
year after the collection of any of these samples. These donors were considered healthy in that they had no known history of
any significant systemic diseases, including, but not limited to, autoimmune disease, diabetes, kidney or liver disease, congestive
heart failure, malignancy, coagulopathy, hepatitis B or C, or HIV. An overview of the characteristics of these unexposed donors is
provided in Table 1.Cell 181, 1–13.e1–e6, June 25, 2020 e2
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ArticleThe LJI Institutional Review Board approved the collection of these samples (LJI; VD-112). At the time of enrollment in the
initial studies, all individual donors provided informed consent that their samples could be used for future studies, including
this study.
Convalescent COVID-19 Donors
The Institutional Review Boards of the University of California, San Diego (UCSD; 200236X) and La Jolla Institute (LJI; VD-214)
approved blood draw protocols for convalescent donors. All human subjects were assessed for capacity using a standardized
and approved assessment. Subjects deemed to have capacity voluntarily gave informed consent prior to being enrolled in the study.
Individuals did not receive compensation for their participation.
Study inclusion criteria included subjects over the age of 18 years, regardless of disease severity, race, ethnicity, gender, preg-
nancy or nursing status, who were willing and able to provide informed consent, or with a legal guardian or representative willing
and able to provide informed consent when the participant could not personally do so. Study exclusion criteria included lack of
willingness or ability to provide informed consent, or lack of an appropriate legal guardian or representative to provide informed
consent.
Blood from convalescent donors was obtained at a UC San Diego Health clinic. Blood was collected in acid citrate dextrose (ACD)
tubes and stored at room temperature prior to processing for PBMC isolation and plasma collection. A separate serum separator
tube (SST) was collected from each donor. Samples were de-identified prior to analysis. Other efforts to maintain the confidentiality
of participants included referring to specimens and other records via an assigned, coded identification number.
Prior to enrollment in the study, donors were asked to provide proof of positive testing for SARS-CoV-2, and screened for clinical
history and/or epidemiological risk factors consistent with the World Health Organization (WHO) or Centers for Disease Control and
Prevention (CDC) case definitions of COVID-19 or Persons Under Investigation (PUI) (https://www.who.int/emergencies/diseases/
novel-coronavirus-2019/technical-guidance/surveillance-and-case-definitions, https://www.cdc.gov/coronavirus/2019-nCoV/hcp/
clinical-criteria.html). Per CDC and WHO guidance, clinical features consistent with COVID-19 included subjective or measured
fever, signs or symptoms of lower respiratory tract illness (e.g., cough or dyspnea). Epidemiologic risk factors included close contact
with a laboratory-confirmed case of SARS-CoV-2 within 14 days of symptom onset or a history of travel to an area with a high rate of
COVID-19 cases within 14 days of symptom onset.
Disease severity was defined as mild, moderate, severe or critical based on a modified version of the WHO interim guidance,
‘‘Clinical management of severe acute respiratory infection when COVID-19 is suspected’’ (WHO Reference Number: WHO/2019-
nCoV/clinical/2020.4). Mild disease was defined as an uncomplicated upper respiratory tract infection (URI) with potential non-
specific symptoms (e.g., fatigue, fever, cough with or without sputum production, anorexia, malaise, myalgia, sore throat, dys-
pnea, nasal congestion, headache; rarely diarrhea, nausea and vomiting) that did not require hospitalization. Moderate disease
was defined as the presence of lower respiratory tract disease or pneumonia without the need for supplemental oxygen, without
signs of severe pneumonia, or a URI requiring hospitalization (including observation admission status). Severe disease was
defined as severe lower respiratory tract infection or pneumonia with fever plus any one of the following: tachypnea (respiratory
rate > 30 breaths per minute), respiratory distress, or oxygen saturation less than 93% on room air. Critical disease was defined as
the need for ICU admission or the presence of acute respiratory distress syndrome (ARDS), sepsis, or septic shock, as defined in
the WHO guidance document.
Convalescent donors were screened for symptoms prior to scheduling blood draws, and had to be symptom-free and approxi-
mately 3 weeks out from symptom onset at the time of the initial blood draw. Following enrollment, whole blood from convalescent
donors was run on a colloidal-gold immunochromatographic ‘lateral flow’ assay to evaluate for prior exposure to SARS-CoV-2. This
assay detects IgM or IgG antibodies directed against recombinant SARS-CoV-2 antigen labeled with a colloidal gold tracer (20/20
BioResponse CoronaCheck). Ninety percent of convalescent donors tested positive for IgM or IgG to SARS-CoV-2 by this assay
(Table 1).
Convalescent donors were California residents, whowere either referred to the study by a health care provider or self-referred. The
majority (75%) of donors had a known sick contact with COVID-19 or suspected exposure to SARS-CoV-2 (Table 1). The most com-
mon symptoms reported were cough, fatigue, fever, anosmia, and dyspnea. Seventy percent of donors experienced mild illness.
Donors were asked to self-report any known medical illnesses. Of note, 65% of these individuals had no known underlying medical
illnesses.
METHOD DETAILS
Peptide Pools
Epitope MegaPool (MP) design and preparation
SARS-CoV-2 virus-specific CD4 and CD8 peptides were synthesized as crude material (A&A, San Diego, CA), resuspended in
DMSO, pooled and sequentially lyophilized as previously reported (Carrasco Pro et al., 2015). SARS-CoV-2 epitopes were predicted
using the protein sequences derived from the SARS-CoV-2 reference (GenBank: MN908947) and IEDB analysis-resource as previ-
ously described (Dhanda et al., 2019; Grifoni et al., 2020). Specifically, CD4 SARS-CoV-2 epitope prediction was carried out using a
previously described approach in Tepitool resource in IEDB (Paul et al., 2015; Paul et al., 2016), to select peptides with median
consensus percentile % 20, similar to what was previously described, but removing the resulting spike glycoprotein epitopese3 Cell 181, 1–13.e1–e6, June 25, 2020
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Articlefrom this prediction (CD4-R (remainder) ‘‘Non-spike’’ MP, n = 221). This approach takes advantage of the extensive cross-reactivity
and repertoire overlap between different HLA class II loci and allelic variants to predict promiscuous epitopes, capable of binding
across the most common HLA class II prototypic specificities (Greenbaum et al., 2011; O’Sullivan et al., 1991; Sidney et al.,
2010a, b; Southwood et al., 1998). The algorithm utilizes predictions for seven common HLA-DR alleles (DRB1*03:01,
DRB1*07:01, DRB1*15:01, DRB3*01:01, DRB3*02:02, DRB4*01:01 and DRB5*01:01) empirically determined to allow coverage of
diverse populations and for different pathogens and antigen systems (Dhanda et al., 2018; Paul et al., 2015).
To investigate in-depth spike-specific CD4 T cells, 15-mer peptides (overlapping by 10 amino acids) spanning the entire antigen
have been synthesized and pooled separately (CD-4 S (spike) MP, n = 253).
In the case of CD8 epitopes, since the overlap between different HLA class I allelic variants and loci is more limited to specific
groups of alleles, or supertypes (Sidney et al., 2008), we targeted a set of the 12 most prominent HLA class I A and B alleles
(A*01:01, A*02:01, A*03:01, A*11:01, A*23:01, A*24:02, B*07:02, B*08:01, B*35:01, B*40:01, B*44:02, B*44:03), which have been
shown to allow broad coverage of the general population. CD8 SARS-CoV-2 epitope prediction was performed as previously re-
ported, using NetMHC pan EL 4.0 algorithm (Jurtz et al., 2017) for the top 12 more frequent HLA alleles and selecting the top 1
percentile predicted epitope per HLA allele clustered with nested/overlap reduction (Grifoni et al., 2020). The 628 predicted CD8 epi-
topes were split in two CD8 MPs containing 314 peptides each (CD8-A and CD8-B). The CMV MP is a pool of previously reported
class I and class II epitopes (Carrasco Pro et al., 2015).
Protein peptide pools
In the case of the protein pools, peptides of 15 amino acid length overlapping by 10 spanning each entire protein sequence were
tested in a single MP (6-253 peptides per pool). Table S1 lists the number of peptides pooled for each of the viral proteins. Upon
request we are prepared to make these MP available to the scientific community for use in a diverse set of investigations.
PBMC isolation
For all samples whole blood was collected in ACD tubes (COVID-19 donors) or heparin coated blood bag (healthy unexposed do-
nors). Whole blood was then centrifuged for 15 min at 1850 rpm to separate the cellular fraction and plasma. The plasma was
then carefully removed from the cell pellet and stored at 20C.
Peripheral blood mononuclear cells (PBMC) were isolated by density-gradient sedimentation using Ficoll-Paque (Lymphoprep,
NycomedPharma, Oslo, Norway) as previously described (Weiskopf et al., 2013). Isolated PBMCwere cryopreserved in cell recovery
media containing 10% DMSO (GIBCO), supplemented with 10% heat inactivated fetal bovine serum, depending on the processing
laboratory, (FBS; Hyclone Laboratories, Logan UT) and stored in liquid nitrogen until used in the assays.
SARS-CoV-2 RBD ELISA
SARS-CoV-2 Receptor Binding Domain (RBD) protein was obtained courtesy of Florian Krammer and Peter Kim (Stadlbauer et al.,
2020). Corning 96-well half-area plates (ThermoFisher 3690) were coated with 1mg/mL SARS-CoV-2 RBD overnight at 4C. ELISA
protocol generally followed that of the Krammer lab, which previously demonstrated specificity (Stadlbauer et al., 2020). Plates
were blocked the next day with 3% milk (Skim Milk Powder ThermoFisher LP0031 by weight/volume) in Phosphate Buffered Saline
(PBS) containing 0.05% Tween-20 (ThermoScientific J260605-AP) for 2 hours at room temperature. Plasma was then added to the
plates and incubated for 1.5 hours at room temperature. Prior to plasma addition to the plates, plasma was heat inactivated at 56C
for 30-60minutes. Plasmawas diluted in 1%milk in 0.05%PBS-Tween 20 starting at a 1:3 dilution and diluting each sample at by 1:3.
Plates were then washed 5 times with 0.05% PBS-Tween 20. Secondary antibodies were diluted in 1%milk in 0.05% Tween-20 and
incubated for 1 hour. For IgG, anti-human IgGperoxidase antibody produced in goat (SigmaA6029) was used at a 1:5000 dilution. For
IgM, anti-human IgM peroxidase antibody produced in goat (Sigma A6907) was used at a 1:10,000 dilution. For IgA, anti-human IgA
horseradish peroxidase antibody (Hybridoma Reagent Laboratory HP6123-HRP) was used at a 1:1,000 dilution. Plates were washed
5 times with 0.05% PBS-Tween 20. Plates were developed with TMB Substrate Kit (ThermoScientific 34021) for 15 minutes at room
temperature. The reaction was stopped with 2M sulfuric acid. Plates were read on a Spectramax Plate Reader at 450 nm using Soft-
Max Pro, and ODs were background subtracted. A positive control standard was created by pooling plasma from six convalescing
COVID-19 patients. Positive control standard was run on each plate and was used to calculate titers (relative units) for all samples
using non-linear regression interpolations, done to quantify the amount of anti-RBD IgG, anti-RBD IgM, and anti-RBD IgA present in
each specimen. Titers were plotted for each specimen and compared to COVID-19 negative specimens. As a second analytical
approach, Area under the curve was also calculated for each specimen to compare COVID-19 to negative specimens, using a base-
line of 0.05 for peak calculations.
OC43 and NL63 coronavirus RBD ELISA
An in-house ELISA at UNC was performed by coating with recombinant S RBD antigens (SARS-CoV-2, SARS-CoV, OC43-CoV and
NL63-CoV) in TBS for 1 h at 37 C. After blocking, we added 1:20 diluted serum and incubated at 37C for 1 h. Antigen-specific
antibodies (Ig) were measured at 405 nm by using alkaline phosphatase conjugated goat anti-human IgG, IgA and IgM Abs and
4-Nitrophenyl phosphate.Cell 181, 1–13.e1–e6, June 25, 2020 e4
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ArticleFlow Cytometry
Direct ex vivo PBMC immune cell phenotyping
For the surface stain, 1x106 PBMCs were resuspended in 100 ml PBS with 2% FBS (FACS buffer) and stained with antibody cocktail
for 1 hour at 4C in the dark. Following surface staining, cells were washed twice with FACS buffer. Cells were then fixed/permea-
bilized for 40min at 4C in the dark using the eBioscience FoxP3 transcription factor buffer kit (ThermoFisher Scientific, Waltham,MA).
Following fixation/permeabilization, cells were washed twice with 1x permeabilization buffer, resuspended in 100 ml permeabilization
buffer and stained with intracellular/intranuclear antibodies for 1 hour at 4C in the dark. Samples were washed twice with 1x per-
meabilization buffer following staining. After the final wash, cells were resuspended in 200ml FACS buffer. All samples were acquired
on a BD FACSymphony cell sorter (BD Biosciences, San Diego, CA). A list of antibodies used in this panel can be found in Table S2.
T cell stimulations
For all flow cytometry assays of stimulated T cells, cryopreserved cells were thawed by diluting them in 10 mL complete RPMI 1640
with 5% human AB serum (Gemini Bioproducts) in the presence of benzonase [20ul/10mL]. All samples were acquired on a ZE5 Cell
analyzer (Bio-rad laboratories), and analyzed with FlowJo software (Tree Star, San Carlos, CA).
Activation induced cell marker assay
Cells were cultured for 24 hours in the presence of SARS-CoV-2 specific MPs [1 mg/ml] or 10 mg/mL PHA in 96-wells U bottom plates
at 1x106 PBMC per well. A stimulation with an equimolar amount of DMSO was performed as negative control, phytohemagglutinin
(PHA, Roche, 1 mg/ml) and stimulation with a combined CD4 and CD8 cytomegalovirus MP (CMV, 1 mg/ml) were included as positive
controls. Supernatants were harvested at 24 hours post-stimulation for multiplex detection of cytokines. Antibodies used in the AIM
assay are listed in Table S4. AIM assays shown in Figures 2 and 3 and AIM assays shown in Figure 6 had five COVID-19 donors in
common and nine Unexposed donors. Full raw data is listed in Table S6.
Intracellular cytokine staining assay
For the intracellular cytokine staining, PBMCwerecultured in thepresenceofSARS-CoV-2specificMPs [1mg/ml] for 9 hours.Golgi-Plug
containing brefeldin A (BD Biosciences, San Diego, CA) andmonensin (Biolegend, San Diego, CA) were added 3 hours into the culture.
Cellswere thenwashedandsurface stained for 30minuteson ice, fixedwith1%ofparaformaldehyde (Sigma-Aldrich, St. Louis,MO) and
kept at 4Covernight. Antibodies used in the ICS assay are listed in Table S5.The gates applied for the identification of IFNg, GzB, TNFa,
or IL-10 production on the total population of CD8+ T cells were defined according to the cells cultured with DMSO for each individual.
Cytokine bead assays
Supernatants were collected from 24-hour stimulation cultures of the AIM assays and stored in 96 well plates at20C. Cytokines in
cell culture supernatants of the same samples used for AIM were quantified using a human Th cytokine panel (13-plex) kit (LEGEND-
plex, Biolegend) according to the manufacturer’s instruction. Supernatants were mixed with beads coated with capture antibodies
specific for IL-5, IL-13, IL-2, IL-6, IL-9, IL-10, IFNg, TNFa, IL-17a, IL-17F, IL-4, IL-21 and IL-22 and incubated on a 96 well filter plate
for 2 hours. Beads were washed and incubated with biotin-labeled detection antibodies for 1 hour, followed by a final incubation with
streptavidin-PE. Beads were analyzed by flow cytometry using a FACS Canto cytometer. Analysis was performed using the
LEGENDplex analysis software v8.0, which distinguishes between the 13 different analytes on basis of bead size and internal dye.
Identification of coronavirus epitopes and associated literature references
To identify coronavirus epitopes and associated references, the IEDBwas searched (on April 16, 2020) utilizing the following queries.
A first query was run to identify references associated with class I restricted CD8 epitopes, which utilized the criteria settings ‘‘An-
tigen’’: Organism =Coronavirus (taxonomy ID 11118); ‘‘Assay’’: Positive assays only; ‘‘Assay’’: T cell assay; ‘‘MHC restriction’’ =MHC
Class II; no parameters were defined for ‘‘Host’’ or ‘‘Disease.’’ This query identified 57 references, which are listed and displayed
under the ‘‘References’’ tab on the results page.
A second query was run to identify references associated with class II restricted CD4 epitopes which utilized the criteria settings
‘‘Antigen’’: Organism = Coronavirus (taxonomy ID 11118); ‘‘Assay’’: Positive assays only; ‘‘Assay’’: T cell assay; ‘‘MHC restriction’’ =
MHC Class II; no parameters were defined for ‘‘Host’’ or ‘‘Disease.’’ This query identified 27 references, which are listed and
displayed under the ‘‘References’’ tab on the results page.
A third query was run to specifically capture epitopes and map them back to the antigen of origin using the setting; ‘‘Antigen’’: Or-
ganism = Coronavirus (taxonomy ID 11118); ‘‘Assay’’: Positive assays only; ‘‘Assay’’: T cell assay; no parameters were defined for
‘‘MHC restriction,’’ ‘‘Host’’ or ‘‘Disease.’’ Results were exported as csv files, and then examined in Excel to tabulate the number
of CD4 and CD8 epitopes recognized in humans, mice, transgenic mice and other hosts associated with each respective antigen.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data and statistical analyses were done in FlowJo 10 and GraphPad Prism 8.4, unless otherwise stated. The statistical details of the
experiments are provided in the respective figure legends. Data plotted in linear scale were expressed asMean + Standard Deviation
(SD). Data plotted in logarithmic scales were expressed as Geometric Mean + Geometric Standard Deviation (SD). Correlation an-
alyses were performed using Spearman, while Mann-Whitney or Wilcoxon tests were applied for unpaired or paired comparisons,
respectively. Details pertaining to significance are also noted in the respective legends. T cell data have been calculated ase5 Cell 181, 1–13.e1–e6, June 25, 2020
ll
Please cite this article in press as: Grifoni et al., Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease
and Unexposed Individuals, Cell (2020), https://doi.org/10.1016/j.cell.2020.05.015
Articlebackground subtracted data or stimulation index. Background subtracted data were derived by subtracting the percentage of AIM+
cells after SARS-CoV-2 stimulation from the DMSO stimulation. Stimulation Index was calculated instead by dividing the percentage
of AIM+ cells after SARS-CoV-2 stimulation with the percentage of AIM+ cells derived from DMSO stimulation. If the AIM+ cells per-
centage after DMSO stimulation was equal to 0, the minimum value across each cohort was used. When two stimuli were combined
together, the percentage of AIM+ cells after SARS-CoV-2 stimulation was combined and either subtracted twice or divided by twice
the value of the percentage of AIM+ cells derived from DMSO stimulation. Additional data analysis techniques are described in the
STAR Methods sections above.Cell 181, 1–13.e1–e6, June 25, 2020 e6
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Figure S1. SARS-CoV-2 Spike Protein RBD Serology, Related to Figure 1
(A-C) ELISA curves for (A) IgG, (B) IgM, and (C) IgA from 10 representative donors. Five COVID-19 cases and
(D-F) Area under the curve (AUC) SARS-CoV-2 spike protein RBD (D) IgG (E) IgM, and (F) IgA, ELISA quantitation, from the same donors and experiments shown
in Figure 1. Geometric mean titers with geometric SDs are indicated. P values are two-tailed Mann-Whitney tests.
ll
Article
Figure S2. Phenotyping Flow Cytometry, Related to Figure 1
Representative gating of CD3+ T cells, CD19+ B cells, CD3-CD19- cells, CD4+ T cells, CD8+ T cells and CD14+ monocytes from donor PBMCs is shown. Briefly,
mononuclear cells were gated out of all events followed by subsequent singlet gating. Live cells are gated as Zombie UV-. Cells were then gated as CD19-PE-
Cy5+, CD3-buv395+ or CD19-CD3- cells. T cells were further subdivided into either CD8-buv805+ or CD4-PerCPefluor710+ populations. CD3-CD19- cells were
defined as CD56-PE-Dazzlebright NK cells, CD56dimCD-16buv737+ NK cells or CD56- monocytes. Monocytes were further classified on differential expression of
CD14-bv510 and CD16.
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Figure S3. SARS-CoV-2-Specific CD4+ T Cell Responses of Recovered COVID-19 Patients, Related to Figure 2
(A) Example flow cytometry gating strategy.
(B) FACS plot examples for controls. DMSO negative control, CMV positive control, PHA positive control.
(C) CMV-specific CD4+ T cells as percentage of AIM+ (OX40+CD137+) CD4+ T cells after stimulation of PBMCs with CMV peptide pool. Data were background
subtracted against DMSO negative control and are shown with geometric mean and geometric standard deviation. Samples were from unexposed donors
(‘‘Unexposed,’’ n = 11) and recovered COVID-19 patients (‘‘COVID-19,’’ n = 10).
(D) Spearman correlation of SARS-CoV-2 spikespecific CD4+ T cells (AIM+ (OX40+CD137+) CD4+ T cells, background subtracted) after stimulation with spike
pool run on the same donors in two independent experiment series run on different dates. COVID-19 patient samples shown in blue. Unexposed donor samples
shown in black.
(E-F) Stimulation index quantitation of AIM+ (OX40+CD137+) CD4+ T cells; the same samples as in Figure 2 and Figure S3C were analyzed.
(G-H) Cytokine levels in the supernatants of AIM assays after stimulation with (G) Spike MP (MP_S), or (H) CD4-R (‘‘Non-spike’’). Data are shown in comparison to
the negative control (DMSO), per donor.
(legend continued on next page)
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(I-J) Cytokine production by CD4+ T cells in response to Non-spike (CD4-R MP) or Spike (MP_S) peptide pools (‘‘CoV antigen (Ag)’’) was confirmed by analyzing
cytokine secretion from the subset of COVID-19 donors determined to have low or negative CD8+ T cell responses (< 0.1% by AIM) to the same peptide pool
determined positive for SARS-CoV-2specific CD4+ T cells by AIM. (I) IL-2. (J) IFNg.
Statistical comparisons across cohorts were performed with the Mann-Whitney test, while paired sample comparisons were performed with the Wilcoxon test.
**p < 0.01; ***p < 0.001. ns not significant.
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Figure S4. SARS-CoV-2-Specific CD8+ T Cell Responses of Recovered COVID-19 Patients, Related to Figure 3
(A) Flow cytometry gating strategy.
(B) SARS-CoV-2specific CD8+ T cells as determined by AIM+ (CD69+CD137+) CD8+ T cells. Response of PBMCs from COVID-19 cases between the negative
control (DMSO) and antigen specific stimulation.
(C) CMV-specific CD8+ T cells as percentage of AIM+ (CD69+CD137+) CD8+ T cells after stimulation of PBMCs with CMV peptide pool. Data were background
subtracted against DMSO negative control and are shown with geometric mean and geometric standard deviation. Samples were from unexposed donors
(‘‘Unexposed,’’ n = 11) and recovered COVID-19 patients (‘‘COVID-19,’’ n = 10).
(D-E) Stimulation index quantitation of AIM+ (CD69+CD137+) CD8+ T cells; the same samples as in Figure 2 and Figure S4C were analyzed.
Statistical comparisons across cohorts were performed with the Mann-Whitney test, while paired sample comparisons were performed with the Wilcoxon test.
**p < 0.01; ***p < 0.001. ns not significant.
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Figure S5. Correlations between SARS-CoV-2-Specific CD4+ T Cells, Antibodies, and CD8+ T Cells, Related to Figure 4
(A) Correlation between SARS-CoV-2 spikespecific CD4+ T cells and anti-spike RBD IgG, using CD4+ T cell stimulation index.
(B) Correlation between SARS-CoV-2 non-spikespecific CD4+ T cells and anti-spike RBD IgG, using CD4+ T cell stimulation index.
(C) Correlation between SARS-CoV-2 spikespecific CD4+ T cells (%) and anti-spike RBD IgA.
(D) Correlation between SARS-CoV-2 spikespecific CD4+ T cells (%) and anti-spike RBD IgA.
(E) Correlation between SARS-CoV-2specific CD4+ T cells and SARS-CoV-2specific CD8+ T cells, using stimulation index. Total MP responses per donor
were used in each case (‘‘Non-spike’’ + ‘‘spike’’ (CD4_R + MP_S) for CD4+ T cells, CD8-A + CD8-B for CD8+ T cells).
Statistical comparisons were performed using Spearman correlation.
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Figure S6. Protein Immunodominance of SARS-CoV-2 Specific CD4+ T Cells in Recovered COVID-19 Patients and Unexposed Donors,
Related to Figure 6
(A) The same data as Figure 6B, but with each unexposed donor color coded.
(B) The same experiment as Figure 6B, but with SARS-CoV-2specific CD4+ T cells measured as percentage of AIM+ (OX40+CD137+) CD4+ T cells, after
background subtraction. COVID-19 cases (top, in blue. n = 10) and unexposed donors (bottom, in white. n = 10).
(legend continued on next page)
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(C) Correlation of SARS-CoV-2specific CD4+ T cells detected using the epitope prediction approach (CD4_RMP) compared against the sum total of all antigen
pools of overlapping peptides (excluding spike), runwith samples from the same donors in two different experiment series. Dotted line indicates 1:1 concordance.
Statistical comparison was performed using Spearman correlation.
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Figure S7. Protein Immunodominance of SARS-CoV-2-Specific CD8+ T Cells in Recovered COVID-19 Patients and Unexposed Donors,
Related to Figure 6
(A) The same data as Figure 6D, but with each unexposed donor color coded.
(B) The same experiment as Figure 6D, but with SARS-CoV-2specific CD8+ T cells measured as percentage of AIM+ (CD69+CD137+) CD8+ T cells, after
background subtraction. COVID-19 cases (top, in red. n = 10) and unexposed donors (bottom, in gray. n = 10).
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